{
  "ticker": "LENZ",
  "company_name": "LENZ",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT02554396",
      "title": "Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Presbyopia",
      "start_date": "2015-09",
      "completion_date": "2015-11",
      "enrollment": 0,
      "sponsor": "LENZ Therapeutics, Inc"
    },
    {
      "nct_id": "NCT06045299",
      "title": "Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Presbyopia, Near Vision, Miosis, Eye Diseases",
      "start_date": "2023-09-27",
      "completion_date": "2025-01-27",
      "enrollment": 0,
      "sponsor": "Corxel Pharmaceuticals"
    },
    {
      "nct_id": "NCT05936489",
      "title": "Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Eye Diseases, Presbyopia, Refractive Errors, Brimonidine Tartrate, Aceclidine, Ophthalmic Solutions",
      "start_date": "2023-07-06",
      "completion_date": "2023-10-03",
      "enrollment": 0,
      "sponsor": "LENZ Therapeutics, Inc"
    },
    {
      "nct_id": "NCT05728944",
      "title": "Phase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Presbyopia, Near Vision, Miosis, Eye Diseases",
      "start_date": "2023-03-06",
      "completion_date": "2024-01-24",
      "enrollment": 0,
      "sponsor": "LENZ Therapeutics, Inc"
    },
    {
      "nct_id": "NCT05753189",
      "title": "Phase 3 Safety Study for the Treatment of Presbyopia Subjects",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Presbyopia, Near Vision, Miosis, Eye Diseases",
      "start_date": "2023-02-21",
      "completion_date": "2024-02-09",
      "enrollment": 0,
      "sponsor": "LENZ Therapeutics, Inc"
    },
    {
      "nct_id": "NCT05294328",
      "title": "Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Presbyopia, Refractive Errors, Eye Diseases",
      "start_date": "2022-05-05",
      "completion_date": "2022-09-10",
      "enrollment": 0,
      "sponsor": "LENZ Therapeutics, Inc"
    },
    {
      "nct_id": "NCT05431543",
      "title": "Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Presbyopia, Refractive Errors, Eye Diseases",
      "start_date": "2022-08-06",
      "completion_date": "2022-12-14",
      "enrollment": 0,
      "sponsor": "LENZ Therapeutics, Inc"
    },
    {
      "nct_id": "NCT06270030",
      "title": "Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Presbyopia",
      "start_date": "2024-03-04",
      "completion_date": "2024-04-10",
      "enrollment": 0,
      "sponsor": "Corxel Pharmaceuticals"
    },
    {
      "nct_id": "NCT05656027",
      "title": "Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Presbyopia, Refractive Error, Near Vision, Miosis, Eye Diseases",
      "start_date": "2022-12-19",
      "completion_date": "2024-01-25",
      "enrollment": 0,
      "sponsor": "LENZ Therapeutics, Inc"
    },
    {
      "nct_id": "NCT03201562",
      "title": "A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Presbyopia",
      "start_date": "2017-04-30",
      "completion_date": "2018-05-20",
      "enrollment": 0,
      "sponsor": "LENZ Therapeutics, Inc"
    }
  ],
  "summary": {
    "total_trials": 10,
    "by_phase": {
      "PHASE2": 4,
      "PHASE3": 4,
      "PHASE1": 2
    },
    "by_status": {
      "COMPLETED": 10
    },
    "active_trials": 0,
    "completed_trials": 10,
    "conditions": [
      "Eye Diseases, Presbyopia, Refractive Errors, Brimonidine Tartrate, Aceclidine, Ophthalmic Solutions",
      "Presbyopia",
      "Presbyopia, Near Vision, Miosis, Eye Diseases",
      "Presbyopia, Refractive Error, Near Vision, Miosis, Eye Diseases",
      "Presbyopia, Refractive Errors, Eye Diseases"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:47:29.737584",
    "search_query": "LENZ",
    "url": "https://clinicaltrials.gov/search?term=LENZ"
  }
}